• LABline
  • Magazine Archive
  • Webinars
  • Whitepapers
  • eBooks
  • Videos
  • Subscribe
    • ID 3961118 © Sebastian Czapnik | Dreamstime.com
    dreamstime_xxl_3961118
    HIV

    Twice-yearly lenacapavir for PrEP reduces HIV infections by 96%

    LABline
    Dec. 3, 2024
    HIV pre-exposure prophylaxis (PrEP) has emerged as a crucial tool for fighting the global HIV epidemic, but researchers say daily pill regimens remain an obstacle to treatment...
    ID 182456892 © Robert Kneschke | Dreamstime.com
    dreamstime_xxl_182456892
    ID 101796561 © Pressmaster | Dreamstime.com
    dreamstime_xxl_101796561
    Courtesy of the NIH
    Transmission electron micrograph of HIV-1 virus particles.
    ID 140145646 © Piotr Adamowicz | Dreamstime.com
    dreamstime_xxl_140145646
    ID 113230282 © Juan Moyano | Dreamstime.com
    dreamstime_xxl_113230282
    ID 62238627 © Chatsimo | Dreamstime.com
    dreamstime_xxl_62238627
    HIV

    Proposed rule to expand access to life-saving organs for people with HIV

    LABline
    Sept. 16, 2024
    Proposal to remove clinical research requirements for transplantation of kidneys and livers from donors with HIV.
    ID 27475005 © Zorandim | Dreamstime.com
    dreamstime_xxl_27475005
    Photo 26225236 © Justin Skinner | Dreamstime.com
    HIV

    Only the urgent and accelerated delivery of HIV services will keep the promise of ending AIDS in children by 2030

    LABline
    July 25, 2024
    Despite significant gains in many countries, critical gaps continue to undermine efforts to end AIDS in children.
    Courtesy of NIAID, NIH
    HIV

    Long-acting injectable cabotegravir for HIV prevention is safe in pregnancy

    LABline
    July 24, 2024
    NIH-sponsored study supports cabotegravir use throughout period of reproductive potential.
    Courtesy of NIAID, NIH
    HIV

    Exploratory analysis associates HIV drug abacavir with elevated cardiovascular disease risk in large global trial

    LABline
    July 24, 2024
    Findings add to body of evidence on cardiovascular risk factors for people with HIV.
    Photo 32052491 © Abhijith Ar | Dreamstime.com
    HIV

    Integrated DNA Technologies introduces new HIV panel

    LABline
    June 25, 2024
    xGen HIV Amplicon Panel provides a single-tube, 2.5-hour workflow designed to enable detection down to 1,000 viral genome copies.
    Courtesy of NIAID, NIH
    HIV

    U.S. clinical trials begin for twice-yearly HIV prevention injection

    LABline
    June 5, 2024
    Studies will focus on priority populations underrepresented in HIV clinical research.
    Photo 158439695 © Clairelucia | Dreamstime.com
    HIV

    Researchers a step closer to a cure for HIV

    LABline
    March 29, 2024
    A new study involving University of Bristol researchers shows a virus-like particle (HLP) can effectively ‘shock and kill’ latent HIV reservoir in those living with chronic HIV...
    Courtesy of NIAID, NIH
    HIV

    Long-acting HIV treatment benefits adults with barriers to daily pill taking and adolescents with suppressed HIV

    LABline
    March 7, 2024
    NIH-funded research networks provide evidence on cabotegravir and rilpivirine in additional populations.

    HIV

    Photo 95973145 © Guernica | Dreamstime.com
    Courtesy of NIAID, NIH
    Courtesy of NIAID, NIH
    Courtesy of NIAID, NIH
    Courtesy of NIAID, NIH
    Photo 115257782 © Oleg Dudko | Dreamstime.com
    Courtesy of NIAID, NIH